Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$119.09
neg -0.13
-0.11%
Today's Range: 118.81 - 119.23 | JNJ Avg Daily Volume: 6,260,900
Last Update: 09/28/16 - 11:37 AM EDT
Volume: 1,257,287
YTD Performance: 16.06%
Open: $119.18
Previous Close: $119.22
52 Week Range: $91.76 - $126.07
Oustanding Shares: 2,735,876,843
Market Cap: 322,231,574,569
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 7
Moderate Buy 2 2 2 2
Hold 7 8 9 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.11 2.22 2.26 2.22
Latest Dividend: 0.80
Latest Dividend Yield: 2.72%
Dividend Ex-Date: 08/19/16
Price Earnings Ratio: 21.45
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
21.45 22.10 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.29% 31.01% 37.46%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.01
Net Income -5.60 0.50 0.13
EPS -3.90 0.40 0.12
Earnings for JNJ:
EBITDA 22.04B
Revenue 70.07B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.63 $1.58 $6.68 $7.09
Number of Analysts 10 8 10 12
High Estimate $1.67 $1.64 $6.70 $7.31
Low Estimate $1.59 $1.55 $6.67 $6.89
Prior Year $1.49 $1.44 $6.20 $6.68
Growth Rate (Year over Year) 9.53% 9.81% 7.82% 6.07%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.
The leadership is quite stark.
It could well be the stock market, not the Fed, that is driving our retail and services.
Its long-term reputation appears to be supporting the shares far more than they deserve.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
Time to lock in gains in JNJ.
There are plenty of doubters about the market and its record highs.
Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.
It depends on the type of test and who's doing the grading.

Columnist Conversations

Decent start to markets today, but then had a quick reversal especially in high beta parts of market.  Bi...
There has been a consistent pattern from the oil markets in the past year. OPEC makes noise about constraining...
yesterday we rolled up a prior play and added an at the money on this momentum name. BOUGHT GWPH NOV 125 CA...
yesterday we added some WDC calls (sorry it's late, i'm still in Chicago and had some internet connection issu...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.